Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

Tirzepatide once weekly for the treatment of obesity

Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. New England Journal of Medicine 2022

Document identifier
CEI-BR-051
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A
Title
Tirzepatide once weekly for the treatment of obesity
Source
New England Journal of Medicine
Year
2022
Volume, issue, pages
387(3):205–216
Digital object identifier
10.1056/NEJMoa2206038
PubMed identifier
35658024
Record type
Journal article
Institute identifier
CEI-BR-051

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Monograph: TirzepatideCompound monograph
Monograph: Maridebart cafraglutideCompound monograph
Trial abstract: SURMOUNT-1Trial abstract
Synthesis: Dual and triple incretin receptor agonists compared with single…Evidence synthesis
Synthesis: Gastrointestinal adverse events with incretin receptor agonistsEvidence synthesis
Synthesis: Tirzepatide in obesity and overweight in adults: effect on the anchor…Evidence synthesis
Synthesis: Tirzepatide in type 2 diabetes mellitus: effect on the anchor outcomeEvidence synthesis
Synthesis: Maridebart cafraglutide in obesity and overweight in adults: effect…Evidence synthesis
Synthesis: Tirzepatide in atherosclerotic cardiovascular disease and…Evidence synthesis
Synthesis: Tirzepatide in obstructive sleep apnoea with obesity: effect on the…Evidence synthesis
Synthesis: Tirzepatide in obesity and overweight in adults: tolerability and…Evidence synthesis
Synthesis: Tirzepatide in type 2 diabetes mellitus: tolerability and…Evidence synthesis
Synthesis: Maridebart cafraglutide in obesity and overweight in adults…Evidence synthesis
Synthesis: Tirzepatide in atherosclerotic cardiovascular disease and…Evidence synthesis
Synthesis: Tirzepatide in obstructive sleep apnoea with obesity: tolerability…Evidence synthesis
Synthesis: Tirzepatide in obesity and overweight in adults: durability of effectEvidence synthesis
Synthesis: Tirzepatide in type 2 diabetes mellitus: durability of effectEvidence synthesis
17 citing documents.

§1.3Subject tags

tirzepatide obesity SURMOUNT

Compound Evidence Institute · CEI-BR-051 · https://compoundevidence.com/bibliography/jastreboff2022/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.